Rhumbline Advisers Arrowhead Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 359,997 shares of ARWR stock, worth $13.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

359,997

Previous 345,979 4.05%

Holding current value

$13.3 Million

Previous $4.41 Million 29.04%

% of portfolio

0.01%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$9.99 - $16.97 $140,039 - $237,885	14,018 Added 4.05%	359,997 $5.69 Million
Q1 2025 Apr 08, 2025	SELL	$12.74 - $21.53 $437,810 - $739,878	-34,365 Reduced 9.04%	345,979 $4.78 Million
Q4 2024 May 29, 2025	BUY	$17.7 - $26.34 $608,260 - $905,174	34,365 Added 9.93%	380,344 $7.15 Million
Q4 2024 Jan 30, 2025	BUY	$17.7 - $26.34 $140,042 - $208,402	7,912 Added 2.12%	380,344 $7.15 Million
Q3 2024 Nov 12, 2024	SELL	$19.36 - $29.54 $205,157 - $313,035	-10,597 Reduced 2.77%	372,432 $7.21 Million
Q2 2024 Aug 01, 2024	BUY	$21.87 - $28.24 $238,907 - $308,493	10,924 Added 2.94%	383,029 $9.95 Million
Q1 2024 May 09, 2024	BUY	$27.21 - $39.48 $1.35 Million - $1.96 Million	49,736 Added 15.43%	372,105 $10.6 Million
Q4 2023 Feb 08, 2024	SELL	$21.2 - $31.03 $392,157 - $573,992	-18,498 Reduced 5.43%	322,369 $9.86 Million
Q3 2023 Nov 09, 2023	SELL	$26.2 - $36.08 $72,233 - $99,472	-2,757 Reduced 0.8%	340,867 $9.16 Million
Q2 2023 Aug 08, 2023	SELL	$25.16 - $41.38 $46,822 - $77,008	-1,861 Reduced 0.54%	343,624 $12.3 Million
Q1 2023 May 11, 2023	SELL	$23.68 - $38.51 $17,665 - $28,728	-746 Reduced 0.22%	345,485 $8.78 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $507,808 - $735,596	18,136 Added 5.53%	346,231 $14 Million
Q3 2022 Nov 10, 2022	BUY	$29.63 - $48.31 $355,085 - $578,947	11,984 Added 3.79%	328,095 $10.8 Million
Q2 2022 Aug 11, 2022	BUY	$27.79 - $50.61 $739,464 - $1.35 Million	26,609 Added 9.19%	316,111 $11.1 Million
Q1 2022 May 12, 2022	BUY	$39.62 - $69.97 $267,593 - $472,577	6,754 Added 2.39%	289,502 $13.3 Million
Q4 2021 Feb 10, 2022	SELL	$58.09 - $82.51 $7,667 - $10,891	-132 Reduced 0.05%	282,748 $18.7 Million
Q3 2021 Nov 12, 2021	BUY	$58.38 - $84.96 $55,694 - $81,051	954 Added 0.34%	282,880 $17.7 Million
Q2 2021 Aug 05, 2021	SELL	$62.15 - $90.32 $438,219 - $636,846	-7,051 Reduced 2.44%	281,926 $23.3 Million
Q1 2021 May 06, 2021	SELL	$61.35 - $90.47 $531,475 - $783,741	-8,663 Reduced 2.91%	288,977 $19.2 Million
Q4 2020 Feb 10, 2021	SELL	$43.82 - $85.37 $94,081 - $183,289	-2,147 Reduced 0.72%	297,640 $22.8 Million
Q3 2020 Nov 12, 2020	SELL	$33.21 - $51.27 $1.11 Million - $1.72 Million	-33,478 Reduced 10.05%	299,787 $12.9 Million
Q2 2020 Aug 13, 2020	BUY	$26.12 - $43.27 $572,916 - $949,084	21,934 Added 7.05%	333,265 $14.4 Million
Q1 2020 May 06, 2020	BUY	$20.56 - $63.12 $122,475 - $376,005	5,957 Added 1.95%	311,331 $8.96 Million
Q4 2019 Feb 05, 2020	BUY	$28.14 - $73.01 $534,997 - $1.39 Million	19,012 Added 6.64%	305,374 $19.4 Million
Q3 2019 Oct 23, 2019	BUY	$26.26 - $34.86 $87,078 - $115,595	3,316 Added 1.17%	286,362 $8.07 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $2.77 Million - $4.58 Million	158,770 Added 127.76%	283,046 $7.5 Million
Q1 2019 May 01, 2019	BUY	$12.05 - $20.18 $100,171 - $167,756	8,313 Added 7.17%	124,276 $2.28 Million
Q4 2018 Jan 31, 2019	BUY	$10.74 - $19.7 $398,969 - $731,815	37,148 Added 47.13%	115,963 $1.44 Million
Q3 2018 Nov 07, 2018	SELL	$14.0 - $20.3 $72,338 - $104,890	-5,167 Reduced 6.15%	78,815 $1.51 Million
Q2 2018 Aug 06, 2018	BUY	$6.37 - $14.02 $534,965 - $1.18 Million	83,982 New	83,982 $1.14 Million

Others Institutions Holding ARWR

# of Institutions

322

Shares Held

99.6M

Call Options Held

444K

Put Options Held

568K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $3.91B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Arrowhead Pharmaceuticals, Inc. Transaction History